SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly)
PFE 24.43-1.9%1:28 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Anthony Wong who wrote (1291)1/11/1999 10:33:00 PM
From: Anthony Wong  Read Replies (2) of 1722
 
01/11 15:32 *MERCK <MRK.N> SAYS FDA GIVES PAIN AND ARTHRITIS DRUG VIOXX 6-MO PRIORITY REVIEW

WEST POINT, Pa., Jan 11 (Reuters) - Pharmaceutical giant Merck & Co. Inc.
on Monday said that the U.S. Food and Drug Administration has assigned a
six-month priority review for its application for Vioxx, the pharmaceutical giant's
proposed competitor to Monsanto Co.'s <MTC.N> Celebrex for pain treament.

Merck said it submitted the application for Vioxx on Nov. 23.

Merck's application for Vioxx includes results from 68 studies involving nearly
10,000 patients. Those studies evaluated the safety and efficacy of the
once-daily, anti-inflammatory medicine for the treatment of the signs and
symptoms of osteoarthritis and for the relief of pain.

Both Vioxx and Celebrex are COX-2 specific enzyme inhibitors being studied to
determine if they result in fewer certain serious gastrointestinal side effects than
nonsteroidal anti-inflammatory drugs, which are medications that are currently
available for the treatment of osteoarthritis and pain.

The FDA recently approved Monsanto's Celebrex can be marketed only as a
treatment for arthritis-related pain.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News